SMi proudly presents its exclusive conference on Drug Discovery, taking place on 27th and 28th March 2017.
In recent years, the Pharma/Biotech industry has undergone radical changes which have increased are understanding of drug discovery and development, however there are still many hurdles that the industry face.
The gap between a laboratory discovery and an approved drug on the market is a decade-long process of laboratory testing, evaluation in animal models and human clinical trials that can cost hundreds of millions. The conference aims to bridge the gaps in approval for drug discovery and development by discussing the latest scientific breakthroughs, exploring novel technologies and approaches that can be used to overcome drug development challenges.
The conference will bring together industry leaders who will highlight future opportunities for novel therapeutic discovery. Some of our featured speakers include
Lorenz Mayr, VP and Global Head, AstraZeneca
Guido Hanaeur, Scientific Director Translational Medicine, Takeda
Ulrich Schopfer, Executive Director, Head Integrated Lead Discovery, Novartis
Yolanda Chong, Principal Scientist, Johnson and Johnson
Matthias Frech, Director, Molecular Interactions and Biophysics, Merck Serono
Wengard Czechtizky, Head of Chemistry, Sanofi
Ulrich Schopfer, Executive Director, head Integrated Lead Discovery, Novartis
Stephen Pickett, Senior Scientific Investigator, GSK
Plus more from AbbVie, UCB Pharma, Eli Lilly, TissUse, Heptares and more.
For more information and to register, kindly visit http://www.drug-discovery.co.uk/evvnt.
Early Bird rates:
Book by 30 November to save GBP 400
Book by 16 December to save GBP 200
Book by 31 January to save GBP 100
In recent years, the Pharma/Biotech industry has undergone radical changes which have increased are understanding of drug discovery and development, however there are still many hurdles that the industry face.
The gap between a laboratory discovery and an approved drug on the market is a decade-long process of laboratory testing, evaluation in animal models and human clinical trials that can cost hundreds of millions. The conference aims to bridge the gaps in approval for drug discovery and development by discussing the latest scientific breakthroughs, exploring novel technologies and approaches that can be used to overcome drug development challenges.
The conference will bring together industry leaders who will highlight future opportunities for novel therapeutic discovery. Some of our featured speakers include
Lorenz Mayr, VP and Global Head, AstraZeneca
Guido Hanaeur, Scientific Director Translational Medicine, Takeda
Ulrich Schopfer, Executive Director, Head Integrated Lead Discovery, Novartis
Yolanda Chong, Principal Scientist, Johnson and Johnson
Matthias Frech, Director, Molecular Interactions and Biophysics, Merck Serono
Wengard Czechtizky, Head of Chemistry, Sanofi
Ulrich Schopfer, Executive Director, head Integrated Lead Discovery, Novartis
Stephen Pickett, Senior Scientific Investigator, GSK
Plus more from AbbVie, UCB Pharma, Eli Lilly, TissUse, Heptares and more.
For more information and to register, kindly visit http://www.drug-discovery.co.uk/evvnt.
Early Bird rates:
Book by 30 November to save GBP 400
Book by 16 December to save GBP 200
Book by 31 January to save GBP 100
